Companies /Healthcare

Regeneron Pharmaceuticals Inc

NASDAQ: REGN Biotechnology
$739.57
▼ $2.55 (−0.34%) today
Markets closed · 10:59pm ET

24/7 Wall St. View

Price Prediction $810.55 +9.7% Our analysts’ 12-month view: target, optimistic case, and floor. REGN price prediction →

REGN at a Glance

Valuation
Market cap
$76.4B
P/E ratio
18.4
Dividend yield
0.49%
Profitability
Revenue (TTM)
$15.5B
Profit margin
27.9%
EPS (TTM)
$40.44
Price
52-week range
$538 – $859
24/7 target
$810.55
Street target
$856.23
Earnings
Next report
Oct 30, 2026

Headquartered in Tarrytown, NY Fiscal year ends December NASDAQ: REGN regeneron.com

About Regeneron

Regeneron Pharmaceuticals is a biotechnology company that invents, develops, and commercializes medicines for serious diseases. Founded and led by physician-scientists, the company has built a portfolio spanning eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Its approved products include EYLEA HD and EYLEA (aflibercept) for retinal diseases, Dupixent (dupilumab, commercialized in collaboration with Sanofi) for type 2 inflammatory conditions, Libtayo (cemiplimab) for cancers, Praluent (alirocumab) for cardiovascular disease, Kevzara (sarilumab) for rheumatoid arthritis, Evkeeza (evinacumab) for severe hypercholesterolemia, and newer products Lynozyfic (linvoseltamab) and Ordspono (odronextamab) in oncology. The company leverages proprietary technologies including VelociSuite for generating optimized fully human and bispecific antibodies, the Regeneron Genetics Center for genetics-driven drug discovery, and genetic medicine platforms. Regeneron maintains significant collaboration agreements with Sanofi (for Dupixent and Kevzara) and Bayer (for EYLEA products outside the U.S.). The company has approximately 50 product candidates in clinical development and is investing in expanding U.S. manufacturing capacity, including a new facility in Saratoga Springs, New York. Updated

Latest Activity

REGNRegeneron
Regular session
$729.05
-4.89%open $766.53

A 4.89% slide to $729.05 takes roughly $3.6 billion off the biotech's market value in one session. Moves this size are rare for a $73.7 billion name, and the close is what matters now.

Read more
Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 9/24/26

  • Cramer pushes back on index-fund supremacy, calling the absolutist version of it wrong
  • Still recommends 50% of savings in an S&P 500 fund as a hedge against your own mistakes
  • Argues the S&P holds far fewer than 500 good stocks, so you buy the bad with the good
  • Caller questions on portfolio structure for young investors, 529 plans, and retirement vs. mad money

Put half in an index fund as insurance, the other half in individual names you have actually done the homework on. Cramer's case is that an S&P 500 fund gives you 8% to 10% a year and mediocrity alongside the winners, which is why he says it will not make you rich on its own.

Read more

REGN Coverage

Load More

Frequently Asked Questions

What does Regeneron do?

Regeneron Pharmaceuticals is a biotechnology company that invents, develops, and commercializes medicines for serious diseases.

What is the REGN stock price target?

24/7 Wall St.'s 12-month price target for REGN is $810.55, rated Buy. The Wall Street consensus target is $856.23. REGN price prediction →